Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

04.11.2023 - TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today presented additional Phase 1 clinical data ... Seite 1

Related Keywords

Texas ,United States ,Sapna Patel ,Stevenc Katz ,Trisalus Life Sciences Inc ,University Of Texas Md Anderson Cancer Center ,Society Of Immunotherapy ,Nasdaq ,Trinav Infusion System ,Progression Free Survival ,Disease Control Rate ,Chief Medical Officer ,